sacituzumab govitecan   Click here for help

GtoPdb Ligand ID: 8253

Synonyms: hRS7-SN-38-ADC | IMMU-132 | sacituzumab govitecan-hziy | Trodelvy®
Approved drug
sacituzumab govitecan is an approved drug (FDA (2020), EMA (2021))
Compound class: Antibody
Comment: IMMU-132 is an antibody-drug conjugate (ADC) with SN-38 (the active metabolite of the topoisomerase inhibitor irinotecan) covalently linked to an anti-TROP-2 monoclonal antibody (see patent US8574575 [2]) [3-4,6]. TROP-2 is a transmembrane glycoprotein, cell surface antigen which has oncogenic activity in cancers of epithelial origin [7], but expression is restricted in normal tissue. Directing SN-38 to cancer cells via TROP-2 binding is predicted to limit toxicity towards healthy tissue/cells.
Click here for help

Ligand Activity Visualisation Charts

These are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts.

✖

View interactive charts of activity data across species
Classification Click here for help
Compound class Antibody
Approved drug? Yes. FDA (2020)  |  EMA (2021)
International Nonproprietary Names Click here for help
INN number INN
10097 sacituzumab govitecan
Synonyms Click here for help
hRS7-SN-38-ADC | IMMU-132 | sacituzumab govitecan-hziy | Trodelvy®
Database Links Click here for help
Specialist databases
IMGT/mAb-DB 559
Other databases
GtoPdb PubChem SID 249565933
Search PubMed clinical trials sacituzumab govitecan
Search PubMed titles sacituzumab govitecan
Search PubMed titles/abstracts sacituzumab govitecan